- Conditions
- Corneal Edema, Corneal Endothelial Dysfunction, Corneal Endothelial Dystrophy, Fuchs Dystrophy, Fuchs Endothelial Corneal Dystrophy, Pseudophakic Bullous Keratopathy, Bullous Keratopathy, Endothelial Dysfunction, Moderate Corneal Endothelial Decompensation
- Interventions
- EO2002, EO2002 low dose, EO2002 mid dose, EO2002 high dose
- Biological
- Lead sponsor
- Emmecell
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 8
- States / cities
- Greater Los Angeles, California • San Diego, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced May 22, 2026, 3:46 AM EDT